Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link When semaglutide and tirzepatide stop working for patients, Im adding in cagrilintide. Cagrilintide can add as much as 9% more weight loss to already used GLP1s such as semaglutide, tirzepatide or Cagrilintide Dosage and Weight Loss Guide PEP DOSE Cagrilintide Research Peptide Information Peptpedia Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet